Breaking News

Novartis to Build New Radioligand Therapy Site in Denton, Texas

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

(Photo credit: stock.adobe.com/MichaelDerrerFuchs)

Novartis has unveiled plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, TX—the company’s fifth in the U.S. and first manufacturing facility in Texas—marking further progress in the company’s $23 billion U.S. investment. The Denton site is expected to create new Novartis jobs in bioengineering, advanced manufacturing, quality and operations, supporting economic growth in Denton and surrounding communities. Construction is scheduled to begin thi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters